Opthea Limited develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead molecule is OPT-302, a soluble form of VEGFR-3, which is in Phase 1/2A clinical trials for the treatment of wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited is based in South Yarra, Australia.
Industry, Sector and Symbol
Industry Drug Manufacturers - Major
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone61 3 9826 0399
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$187,574.00
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable
Opthea (ASX:OPT) Frequently Asked Questions
What is Opthea's stock symbol?
Opthea trades on the ASX under the ticker symbol "OPT."
Has Opthea been receiving favorable news coverage?
News headlines about OPT stock have been trending somewhat negative this week, according to InfoTrie Sentiment. The research firm identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Opthea earned a daily sentiment score of -1.2 on InfoTrie's scale. They also gave media stories about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the near term.
Who are some of Opthea's key competitors?
Some companies that are related to Opthea include Vectura Group (VEC), Medical Developments International (MVP), Eco Animal Health Group (EAH), BEXIMCO PHARMAC/S GDR REGS (BXP), Trilogy International Partners (TRL), Pharmaxis (PXS), Allergy Therapeutics (AGY), Vita Life Sciences (VLS), Futura Medical (FUM), Cathay International (CTI), Patrys (PAB), Recce Pharmaceuticals (RCE), Avivagen (VIV), Antisense Therapeutics (ANP) and NanoViricides (NNVC).
Who are Opthea's key executives?
Opthea's management team includes the folowing people:
- Dr. Megan Baldwin Ph.D., MAICD, MD, CEO & Exec. Director
- Mr. Michael Tonroe, CFO & Company Sec.
- Mr. Richard Chadwick Ph.D., Head of Intellectual Property
- Dr. Michael Gerometta, Head of CMC Devel.
- Dr. Ian Leitch, Director of Clinical Research
What is Opthea's stock price today?
One share of OPT stock can currently be purchased for approximately A$0.65.
How big of a company is Opthea?
Opthea has a market capitalization of $162.12 million and generates $187,574.00 in revenue each year.
What is Opthea's official website?
How can I contact Opthea?
The company can be reached via phone at 61 3 9826 0399.
MarketBeat Community Rating for Opthea (ASX OPT)
MarketBeat's community ratings are surveys of what our community members think about Opthea and other stocks. Vote "Outperform" if you believe OPT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OPT will underperform the S&P 500 over the long term. You may vote once every thirty days.
